Press Releases


Lilly to Participate in Evercore ISI 3rd Annual HealthCONx Conference

November 24, 2020

Tags |  Financial

INDIANAPOLIS , Nov. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Evercore ISI 3 rd Annual HealthCONx Conference on Tuesday, December 1, 2020 . Michael Mason , Lilly senior vice president and president of Lilly Diabetes and Connected Care, will participate in a




Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19

November 20, 2020

Tags |  Product

- Bamlanivimab emerged from collaboration between Lilly and Vancouver-based AbCellera INDIANAPOLIS , Nov. 20, 2020 /PRNewswire/ -- Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use




Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

November 20, 2020

Tags |  Corporate

Research collaboration using ARCUS genome editing technology will initially include three gene targets, with right to select three additional gene targets; lead program focused on Duchenne Muscular Dystrophy   Precision will receive $100 million cash upfront and an equity investment by Lilly of $35




Baricitinib Receives Emergency Use Authorization from the FDA for the Treatment of Hospitalized Patients with COVID-19

November 19, 2020

Tags |  Product

- ACTT-2 data serve as basis for EUA, the second COVID-19 authorization for a Lilly treatment   - Authorization enables use of baricitinib in combination with remdesivir in hospitalized patients needing oxygen INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and




Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes

November 19, 2020

Tags |  Product

BURGDORF, Switzerland and INDIANAPOLIS , Nov. 19, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Ypsomed (SWX: YPSN) announced today a non-exclusive, global agreement to advance an automated insulin delivery system as part of Lilly 's connected diabetes solutions.




Jardiance® reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial

November 18, 2020

Tags |  Product

- In new results published in The Lancet Diabetes & Endocrinology, Jardiance reduced the risk of total (first plus recurrent) cardiovascular events including 3P-MACE, hospitalization for heart failure and all-cause hospitalization versus placebo in adults with type 2 diabetes and established




Lilly to Participate in Wolfe Research Virtual Healthcare Conference

November 12, 2020

Tags |  Financial

INDIANAPOLIS , Nov. 12, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) will participate in the Wolfe Research Virtual Healthcare Conference on Wednesday, November 18, 2020 . Joshua Smiley , senior vice president and Lilly 's chief financial officer, will participate in a virtual fireside




Lilly to Participate in Bernstein Operational Decisions Conference

November 12, 2020

Tags |  Financial

INDIANAPOLIS , Nov. 12, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) will participate in the Bernstein Operational Decisions Conference on Monday, November 16, 2020 . Andrew Adams , Ph.D., vice president of new therapeutic modalities and scientific leader for Lilly 's anti-COVID-19




Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program

November 11, 2020

Tags |  Financial

Webcast will not include results from any Phase 3 clinical trials INDIANAPOLIS , Nov. 11, 2020 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in




Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19

November 9, 2020

Tags |  Product

- Bamlanivimab is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in high-risk patients   - U.S. government will allocate 300,000 doses of bamlanivimab to high-risk patients, with no out-of-pocket costs for the medication INDIANAPOLIS , Nov.